{"id":"W4313252429","doi":"10.1016/j.jtct.2022.12.017","title":"Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Kite Pharma; Sanofi Genzyme; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; TG Therapeutics; StemCyte; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; HistoGenetics; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Mallinckrodt Pharmaceuticals; Astellas Pharma US; CSL Behring; Eli Lilly and Company; Bristol-Myers Squibb; Amgen; Medac; Jazz Pharmaceuticals; Be The Match Foundation","keywords":"Medicine; Cyclophosphamide; Internal medicine; Transplantation; Incidence (geometry); Bone marrow; Clinical trial; Prospective cohort study; Clinical endpoint; Surgery; Hematopoietic stem cell transplantation; Hematopoietic cell; Gastroenterology; Oncology; Chemotherapy; Haematopoiesis; Stem cell","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001251233,0.0004694568,0.001036567,0.0004371085,0.0002167356,0.0000365099,0.00018074,0.0003082656,0.0004097007],"category_scores_gemma":[0.00002472674,0.0004577478,0.0003617809,0.0005858195,0.0001602439,0.0002209236,0.000008356725,0.0005915781,0.000007186475],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001635589,"about_ca_system_score_gemma":0.0003430145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007124218,"about_ca_topic_score_gemma":0.0003313886,"domain_scores_codex":[0.9953656,0.0005354672,0.001682929,0.0008143039,0.001160922,0.0004407678],"domain_scores_gemma":[0.9983123,0.0005346641,0.0004404108,0.0002703781,0.0002348918,0.0002073844],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3177208,0.003165708,0.51445,0.0005547054,0.0008722571,0.0005435695,0.0121213,0.0001565436,0.147358,0.0002617717,0.000007387688,0.002788014],"study_design_scores_gemma":[0.3395593,0.004607268,0.5946144,0.0007032659,0.001225908,0.000257772,0.001364158,0.002256315,0.05311251,0.001197195,0.00006219814,0.001039741],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904444,0.0004110203,0.002335218,0.0001845365,0.0007488838,0.004341577,0.001249231,0.0001305918,0.0001544968],"genre_scores_gemma":[0.9909803,0.001879364,0.003045477,0.0001574869,0.00006715725,0.0003991918,0.00330721,0.00008145444,0.00008237516],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09424544,"threshold_uncertainty_score":0.9997874,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04516008171446839,"score_gpt":0.3226275748341489,"score_spread":0.2774674931196805,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}